1.Bloodstream Infections and Clinical Significance of Healthcare-associated Bacteremia: A Multicenter Surveillance Study in Korean Hospitals.
Jun Seong SON ; Jae Hoon SONG ; Kwan Soo KO ; Joon Sup YEOM ; Hyun Kyun KI ; Shin Woo KIM ; Hyun Ha CHANG ; Seong Yeol RYU ; Yeon Sook KIM ; Sook In JUNG ; Sang Yop SHIN ; Hee Bok OH ; Yeong Seon LEE ; Doo Ryeon CHUNG ; Nam Yong LEE ; Kyong Ran PECK
Journal of Korean Medical Science 2010;25(7):992-998
Recent changes in healthcare systems have changed the epidemiologic paradigms in many infectious fields including bloodstream infection (BSI). We compared clinical characteristics of community-acquired (CA), hospital-acquired (HA), and healthcare-associated (HCA) BSI. We performed a prospective nationwide multicenter surveillance study from 9 university hospitals in Korea. Total 1,605 blood isolates were collected from 2006 to 2007, and 1,144 isolates were considered true pathogens. HA-BSI accounted for 48.8%, CA-BSI for 33.2%, and HCA-BSI for 18.0%. HA-BSI and HCA-BSI were more likely to have severe comorbidities. Escherichia coli was the most common isolate in CA-BSI (47.1%) and HCA-BSI (27.2%). In contrast, Staphylococcus aureus (15.2%), coagulase-negative Staphylococcus (15.1%) were the common isolates in HA-BSI. The rate of appropriate empiric antimicrobial therapy was the highest in CA-BSI (89.0%) followed by HCA-BSI (76.4%), and HA-BSI (75.0%). The 30-day mortality rate was the highest in HA-BSI (23.0%) followed by HCA-BSI (18.4%), and CA-BSI (10.2%). High Pitt score and inappropriate empirical antibiotic therapy were the independent risk factors for mortality by multivariate analysis. In conclusion, the present data suggest that clinical features, outcome, and microbiologic features of causative pathogens vary by origin of BSI. Especially, HCA-BSI shows unique clinical characteristics, which should be considered a distinct category for more appropriate antibiotic treatment.
Adult
;
Aged
;
Anti-Bacterial Agents/therapeutic use
;
Bacteremia/drug therapy/*epidemiology/microbiology/mortality
;
Community-Acquired Infections/drug therapy/*epidemiology/microbiology/mortality
;
Cross Infection/drug therapy/*epidemiology/microbiology/mortality
;
Humans
;
Korea/epidemiology
;
Male
;
Middle Aged
;
Prospective Studies
;
Risk Factors
;
Treatment Outcome
;
Young Adult
2.Clinical analysis of 77 liver failure patients with nosocomially infected septicemia.
Wei-ping HE ; Hui-fen WANG ; Hai-bin SU
Chinese Journal of Experimental and Clinical Virology 2004;18(3):287-288
OBJECTIVETo study the clinical characteristics and preventive measures of liver failure with nosocomial septicemia.
METHODSRetrospective analysis of nosocomial septicemia seen between 2001 and 2002 was carried out in our hospital.
RESULTSIncidence of nosocomial septicemia was 0.61%, mortality was 14.29%, the main pathogen was Escherichia coli, the drug resistance occurred in most pathogens to the commonly used antibiotics.
CONCLUSIONIn order to reduce nosocomial septicemia, antibiotics should be used rationally, should be paid attention to bacterial culture and antibiotic sensitivity, and preventive measures should be taken.
Adolescent ; Adult ; Aged ; Ampicillin ; therapeutic use ; Anti-Bacterial Agents ; therapeutic use ; Bacteremia ; epidemiology ; etiology ; mortality ; China ; epidemiology ; Cross Infection ; drug therapy ; epidemiology ; mortality ; Drug Resistance, Bacterial ; Escherichia coli Infections ; Female ; Humans ; Incidence ; Klebsiella Infections ; Klebsiella pneumoniae ; drug effects ; Liver Failure ; complications ; epidemiology ; mortality ; Male ; Middle Aged ; Retrospective Studies
3.Prevalence and Clinical Impact of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolated From Hospitalized Patients.
Young Rae KOH ; Kye Hyung KIM ; Chulhun L CHANG ; Jongyoun YI
Annals of Laboratory Medicine 2016;36(3):235-243
BACKGROUND: We estimated the prevalence and clinical impact of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA). The concordance between macromethod and glycopeptide resistance detection (GRD) E tests was determined. In addition, predictors of clinical outcomes in hospitalized patients with S. aureus bacteremia (SAB) or pneumonia (SAP) were evaluated. METHODS: We obtained 229 consecutive S. aureus isolates from all hospitalized patients at two university hospitals located in Busan and Yangsan, Korea. Standard, macromethod, and GRD E tests were performed. Additionally, we reviewed the medical records of all patients. Among the 229 patients, predictors of clinical outcomes were analyzed for 107 patients with SAB and 39 with SAP. RESULTS: Among the 229 isolates, 34.5% of S. aureus isolates and 50.7% of methicillin-resistant S. aureus isolates exhibited the hVISA phenotype based on the macromethod E test. hVISA was nearly associated with treatment failure in patients with SAB (P=0.054) and was significantly associated with treatment failure in patients with SAP (P=0.014). However, hVISA was not associated with 30-day mortality in patients with SAB or SAP. The concordance between the macromethod and GRD E tests was 84.2%. CONCLUSIONS: hVISA is quite common in the southeastern part of Korea. hVISA is associated with treatment failure in patients with SAP.
Aged
;
Anti-Bacterial Agents/*pharmacology/therapeutic use
;
Bacteremia/drug therapy/epidemiology/microbiology
;
Drug Resistance, Bacterial/*drug effects
;
Female
;
Hospital Mortality
;
Hospitalization
;
Humans
;
Male
;
Methicillin-Resistant Staphylococcus aureus/drug effects/isolation & purification
;
Microbial Sensitivity Tests
;
Middle Aged
;
Phenotype
;
Pneumonia/drug therapy/epidemiology/microbiology
;
Prevalence
;
Republic of Korea/epidemiology
;
Staphylococcus aureus/*drug effects/isolation & purification
;
Teicoplanin/pharmacology
;
Vancomycin/pharmacology/*therapeutic use
4.Burkholderia Sepsis in Children as a Hospital-Acquired Infection.
Kyu Yeun KIM ; Dongeun YONG ; Kyungwon LEE ; Ho Seong KIM ; Dong Soo KIM
Yonsei Medical Journal 2016;57(1):97-102
PURPOSE: Hospital-acquired Burkholderia cepacia (B. cepacia) infection are not commonly recorded in patients without underlying lung disease, such as cystic fibrosis and chronic granulomatous disease. However, in 2014, B. cepacia appeared more frequently in pediatric blood samples than in any other year. In order to access this situation, we analyzed the clinical characteristics of B. cepacia infections in pediatric patients at our hospital. MATERIALS AND METHODS: We conducted a retrospective study of blood isolates of B. cepacia taken at our hospital between January 2004 and December 2014. Patient clinical data were obtained by retrospective review of electronic medical records. We constructed a dendrogram for B. cepacia isolates from two children and five adult patients. RESULTS: A total of 14 pediatric patients and 69 adult patients were identified as having B. cepacia bacteremia. In 2014, higher rates of B. cepacia bacteremia were observed in children. Most of them required Intensive Care Unit (ICU) care (12/14). In eleven children, sputum cultures were examined, and five of these children had the same strain of B. cepacia that grew out from their blood samples. Antibiotics were administered based on antibiotic sensitivity results. Four children expired despite treatment. Compared to children, there were no demonstrative differences in adults, except for history of ICU care. CONCLUSION: Although there were not many pediatric cases at our hospital, awareness of colonization through hospital-acquired infection and effective therapy for infection of B. cepacia is needed, as it can cause mortality and morbidity.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Anti-Bacterial Agents/therapeutic use
;
Bacteremia/drug therapy/*epidemiology
;
Burkholderia Infections/blood/drug therapy/*epidemiology
;
Burkholderia cepacia/drug effects/*isolation & purification
;
Child
;
Child, Preschool
;
Cross Infection/blood/*diagnosis/drug therapy/mortality
;
Disease Outbreaks
;
Female
;
Humans
;
Incidence
;
Infant
;
*Intensive Care Units
;
Male
;
Microbial Sensitivity Tests
;
Middle Aged
;
Republic of Korea/epidemiology
;
Retrospective Studies
;
Treatment Outcome
;
Young Adult
5.Risk Factors for Occurrence and 30-Day Mortality for Carbapenem-Resistant Acinetobacter baumannii Bacteremia in an Intensive Care Unit.
Song Yee KIM ; Ji Ye JUNG ; Young Ae KANG ; Joo Eun LIM ; Eun Young KIM ; Sang Kook LEE ; Seon Cheol PARK ; Kyung Soo CHUNG ; Byung Hoon PARK ; Young Sam KIM ; Se Kyu KIM ; Joon CHANG ; Moo Suk PARK
Journal of Korean Medical Science 2012;27(8):939-947
To assess the risk factors for carbapenem-resistant Acinetobacter baumannii (CRAB) bacteremia and for 30-day mortality in patients with CRAB bacteremia in the intensive care unit (ICU), we conducted a retrospective study in the ICU at Severance Hospital in Korea from January 2008 to December 2009. Patients who acquired CRAB bacteremia in the ICU were enrolled as the case group and patients whose specimens of blood culture, sputum/endotracheal aspirate and urine revealed no AB were enrolled as controls. The case group comprised 106 patients and 205 patients were included as controls. Risk factors independently associated with CRAB bacteremia included prior chemotherapy or radiotherapy treatment (Odds ratio [OR], 3.6; P = 0.003), recent central venous catheter insertion (OR, 5.7; P < 0.001) or abdominal drainage insertion (OR, 21.9; P = 0.004), the number of antibiotics treated with (OR, 1.3; P = 0.016), and respiratory failure in the ICU (OR, 2.5; P = 0.035). The 30-day mortality was 79.8%. Renal failure during ICU stay was independently associated with 30-day mortality (OR, 3.7; P = 0.047). It is important to minimize invasive procedures, and to restrict excessive use of antibiotics, especially in immunocompromised patients, in order to prevent the development of CRAB bacteremia. Greater concern for CRAB bacteremia patients is needed when renal failure develops during ICU stay.
Acinetobacter Infections/drug therapy/epidemiology/*mortality
;
Acinetobacter baumannii/*drug effects
;
Adult
;
Aged
;
Anti-Bacterial Agents/*pharmacology/therapeutic use
;
Bacteremia/drug therapy/epidemiology/*mortality
;
Carbapenems/*pharmacology/therapeutic use
;
Case-Control Studies
;
Drug Resistance, Multiple, Bacterial
;
Female
;
Humans
;
Immunocompromised Host
;
Intensive Care Units
;
Male
;
Middle Aged
;
Odds Ratio
;
Renal Insufficiency/etiology
;
Retrospective Studies
;
Risk Factors
;
Survival Rate
;
Time Factors
6.Risk Factors for Mortality in Patients with Serratia marcescens Bacteremia.
Sun Bean KIM ; Yong Duk JEON ; Jung Ho KIM ; Jae Kyoung KIM ; Hea Won ANN ; Heun CHOI ; Min Hyung KIM ; Je Eun SONG ; Jin Young AHN ; Su Jin JEONG ; Nam Su KU ; Sang Hoon HAN ; Jun Yong CHOI ; Young Goo SONG ; June Myung KIM
Yonsei Medical Journal 2015;56(2):348-354
PURPOSE: Over the last 30 years, Serratia marcescens (S. marcescens) has emerged as an important pathogen, and a common cause of nosocomial infections. The aim of this study was to identify risk factors associated with mortality in patients with S. marcescens bacteremia. MATERIALS AND METHODS: We performed a retrospective cohort study of 98 patients who had one or more blood cultures positive for S. marcescens between January 2006 and December 2012 in a tertiary care hospital in Seoul, South Korea. Multiple risk factors were compared with association with 28-day all-cause mortality. RESULTS: The 28-day mortality was 22.4% (22/98 episodes). In a univariate analysis, the onset of bacteremia during the intensive care unit stay (p=0.020), serum albumin level (p=0.011), serum C-reactive protein level (p=0.041), presence of indwelling urinary catheter (p=0.023), and Sequential Oran Failure Assessment (SOFA) score at the onset of bacteremia (p<0.001) were significantly different between patients in the fatal and non-fatal groups. In a multivariate analysis, lower serum albumin level and an elevated SOFA score were independently associated with 28-day mortality [adjusted odds ratio (OR) 0.206, 95% confidential interval (CI) 0.044-0.960, p=0.040, and adjusted OR 1.474, 95% CI 1.200-1.810, p<0.001, respectively]. CONCLUSION: Lower serum albumin level and an elevated SOFA score were significantly associated with adverse outcomes in patients with S. marcescens bacteremia.
Adult
;
Aged
;
Aged, 80 and over
;
Anti-Bacterial Agents/therapeutic use
;
Bacteremia/drug therapy/microbiology/*mortality
;
Cross Infection/mortality
;
Female
;
Humans
;
Intensive Care Units
;
Male
;
Middle Aged
;
Multiple Organ Failure
;
Republic of Korea/epidemiology
;
Retrospective Studies
;
Risk Factors
;
Serratia Infections/diagnosis/drug therapy/*mortality
;
Serratia marcescens/drug effects/*isolation & purification
;
Severity of Illness Index
;
Survival Rate
;
Time Factors
;
Treatment Outcome